86 related articles for article (PubMed ID: 23050818)
1. Use of the cardioprotectants thymosin β4 and dexrazoxane during congenital heart surgery: proposal for a randomized, double-blind, clinical trial.
Stromberg D; Raymond T; Samuel D; Crockford D; Stigall W; Leonard S; Mendeloff E; Gormley A
Ann N Y Acad Sci; 2012 Oct; 1270():59-65. PubMed ID: 23050818
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of thymosin β4 in myocardial infarct and heart failure.
Stark C; Taimen P; Tarkia M; Pärkkä J; Saraste A; Alastalo TP; Savunen T; Koskenvuo J
Ann N Y Acad Sci; 2012 Oct; 1269():117-24. PubMed ID: 23045979
[TBL] [Abstract][Full Text] [Related]
3. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice.
Polanski AK; Ebner A; Ebner B; Hofmann A; Steinbronn N; Brandt A; Forkmann M; Tausche AK; Morawietz H; Strasser RH; Wunderlich C
J Cardiovasc Pharmacol; 2013 Jun; 61(6):545-52. PubMed ID: 23474841
[TBL] [Abstract][Full Text] [Related]
5. Thymosin β4 and cardiac protection: implication in inflammation and fibrosis.
Gupta S; Kumar S; Sopko N; Qin Y; Wei C; Kim IK
Ann N Y Acad Sci; 2012 Oct; 1269():84-91. PubMed ID: 23045975
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
7. Progress on the Function and Application of Thymosin β4.
Xing Y; Ye Y; Zuo H; Li Y
Front Endocrinol (Lausanne); 2021; 12():767785. PubMed ID: 34992578
[TBL] [Abstract][Full Text] [Related]
8. Development of thymosin beta4 for treatment of patients with ischemic heart disease.
Crockford D
Ann N Y Acad Sci; 2007 Sep; 1112():385-95. PubMed ID: 17947592
[TBL] [Abstract][Full Text] [Related]
9. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
[TBL] [Abstract][Full Text] [Related]
10. Thymosin β4 sustained release from poly(lactide-co-glycolide) microspheres: synthesis and implications for treatment of myocardial ischemia.
Thatcher JE; Welch T; Eberhart RC; Schelly ZA; DiMaio JM
Ann N Y Acad Sci; 2012 Oct; 1270():112-9. PubMed ID: 23050826
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection by Thymosin Beta 4.
Pipes GT; Yang J
Vitam Horm; 2016; 102():209-26. PubMed ID: 27450736
[TBL] [Abstract][Full Text] [Related]
12. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of thymosin β4 in a mouse model of lung fibrosis.
Conte E; Genovese T; Gili E; Esposito E; Iemmolo M; Fruciano M; Fagone E; Pistorio MP; Crimi N; Cuzzocrea S; Vancheri C
Ann N Y Acad Sci; 2012 Oct; 1269():69-73. PubMed ID: 23045972
[TBL] [Abstract][Full Text] [Related]
14. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
15. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.
Treadwell T; Kleinman HK; Crockford D; Hardy MA; Guarnera GT; Goldstein AL
Ann N Y Acad Sci; 2012 Oct; 1270():37-44. PubMed ID: 23050815
[TBL] [Abstract][Full Text] [Related]
16. Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts.
Neckář J; Boudíková A; Mandíková P; Stěrba M; Popelová O; Mikšík I; Dabrowská L; Mráz J; Geršl V; Kolář F
Can J Physiol Pharmacol; 2012 Sep; 90(9):1303-10. PubMed ID: 22913659
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Ruff D; Crockford D; Girardi G; Zhang Y
Ann N Y Acad Sci; 2010 Apr; 1194():223-9. PubMed ID: 20536472
[TBL] [Abstract][Full Text] [Related]
18. Advances in the basic and clinical applications of thymosin β4.
Goldstein AL; Kleinman HK
Expert Opin Biol Ther; 2015; 15 Suppl 1():S139-45. PubMed ID: 26096726
[TBL] [Abstract][Full Text] [Related]
19. Thymosin β4 protein therapy for cardiac repair.
Dubé KN; Bollini S; Smart N; Riley PR
Curr Pharm Des; 2012; 18(6):799-806. PubMed ID: 22236126
[TBL] [Abstract][Full Text] [Related]
20. Cardiac repair with thymosin β4 and cardiac reprogramming factors.
Srivastava D; Ieda M; Fu J; Qian L
Ann N Y Acad Sci; 2012 Oct; 1270():66-72. PubMed ID: 23050819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
